KPC Pharmaceuticals (600422.SS) Stock Price
KPC Pharmaceuticals Price
Revenue has compounded at 9.6% per year over the past 19 years to 6.58 B CNY. Earnings per share have grown at 30.0% per year over the last 19 years. KPC Pharmaceuticals's net margin stands at 5.3%, broadly stable from 6.2% several years earlier. KPC Pharmaceuticals currently offers a dividend yield of about 3.59%. The payout ratio is around 68% of earnings. The dividend has grown at 18.0% per year over the past 15 years. Analysts set a median price target of 19.12 CNY, implying 128.7% above the current price. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus.
KPC Pharmaceuticals stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
KPC Pharmaceuticals business model & stock analysis
Frequently asked questions about KPC Pharmaceuticals
Analysts currently set an average price target of 19.12 CNY for the KPC Pharmaceuticals stock (median: 19.12 CNY), implying +125.7 % versus the latest price. The consensus is based on 9 analyst ratings.
9 analysts currently rate the KPC Pharmaceuticals stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect KPC Pharmaceuticals to generate revenue of 4.36 B CNY and earnings per share of -0.19 CNY.
Converted at the current exchange rate, the KPC Pharmaceuticals share trades at 1.14 EUR (8.36 CNY).
The KPC Pharmaceuticals share (600422.SS) is listed on 1 stock exchanges, including: Shanghai (600422.SS).
The expected revenue of KPC Pharmaceuticals is 4.36 B CNY. This figure is based on current financial data and reflects the company's business performance.
The expected profit of KPC Pharmaceuticals is -150.72 M CNY. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of KPC Pharmaceuticals is currently -44.28. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the KPC Pharmaceuticals stock.
The price-to-sales ratio (P/S) of KPC Pharmaceuticals is currently 1.53. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the KPC Pharmaceuticals stock.
The Eulerpool Quality Score for KPC Pharmaceuticals is 3/10.
The ISIN of KPC Pharmaceuticals is CNE0000015P8. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of KPC Pharmaceuticals is 600422.SS. The ticker symbol is used to trade KPC Pharmaceuticals shares on the stock exchange.
KPC Pharmaceuticals stock
KPC Pharmaceuticals Peer Group
KPC Pharmaceuticals Ticker
KPC Pharmaceuticals FIGI
All fundamentals and in-depth analysis of KPC Pharmaceuticals
Our stock analysis for KPC Pharmaceuticals stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of KPC Pharmaceuticals. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.